Quick Answer
SUTRO BIOPHARMA, INC. reported Net Income Loss of -$191.09 million for the year ending 2025.
- SUTRO BIOPHARMA, INC. showed an increase of +16.0% in Net Income Loss from 2024 to 2025.
- This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$1.11 million | Q2 2017: -$1.81 million | Q3 2017: -$1.42 million | Q4 2017: -$15.34 million | Q1 2018: -$12.05 million | Q2 2018: -$11.54 million | Q3 2018: -$10.24 million | Q4 2018: -$1.49 million | Q1 2019: -$14.25 million | Q2 2019: -$13.79 million | Q3 2019: -$12.91 million | Q4 2019: -$14.79 million | Q1 2020: -$19.60 million | Q2 2020: $29.87 million | Q3 2020: $17.14 million | Q4 2020: -$59.54 million | Q1 2021: -$30.36 million | Q2 2021: -$6.15 million | Q3 2021: -$30.90 million | Q1 2022: -$39.11 million | Q2 2022: -$26.01 million | Q3 2022: -$19.49 million | Q1 2023: -$50.05 million | Q2 2023: -$38.52 million | Q3 2023: -$49.28 million | Q1 2024: -$58.21 million | Q2 2024: -$48.02 million | Q3 2024: -$48.79 million | Q1 2025: -$75.97 million | Q2 2025: -$11.50 million | Q3 2025: -$56.86 million.
- Over the full 10 years of available data (2016 to 2025), SUTRO BIOPHARMA, INC.'s Net Income Loss has declined by 11,327.1%.
- Historical annual values: Fiscal year 2025: -$191.09 million | Fiscal year 2024: -$227.46 million | Fiscal year 2023: -$106.79 million | Fiscal year 2022: -$119.20 million | Fiscal year 2021: -$105.54 million | Fiscal year 2020: -$32.13 million | Fiscal year 2019: -$119.20 million | Fiscal year 2018: -$35.32 million | Fiscal year 2017: -$19.69 million | Fiscal year 2016: $1.70 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: